Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial

Simple summaryStereotactic body radiotherapy (SBRT) of 35–36.25 Gy in five fractions with the CyberKnife System yields excellent control with low toxicity in low–intermediate-risk prostate cancer patients. We found no differences in biochemical control and overall survival in relation to dose. There...

詳細記述

書誌詳細

出版年:	Frontiers in Oncology
主要な著者:	Valentina Borzillo, Esmeralda Scipilliti, Donato Pezzulla, Marcello Serra, Gianluca Ametrano, Giuseppe Quarto, Sisto Perdonà, Sabrina Rossetti, Sandro Pignata, Anna Crispo, Piergiacomo Di Gennaro, Valentina D’Alesio, Cecilia Arrichiello, Francesca Buonanno, Simona Mercogliano, Antonio Russo, Antonio Tufano, Rossella Di Franco, Paolo Muto
フォーマット:	論文
言語:	英語
出版事項:	Frontiers Media S.A. 2023-11-01
主題:	clinical outcome toxicity low-and intermediate-risk radiotherapy prostate cancer stereotactic body radiation
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1270498/full